Abstract: The present invention provides systems, devices, and methods employing fiber optic shape and position tracking. The systems, devices, and methods permit measurement of and continuous tracking of the shape and position of objects whose shape dynamically changes with time. Applications include tracking and monitoring of endoscopes for diagnostic and surgical procedures.

Abstract: There is herein described a nanovesicle comprising a bilayer of porphyrin-phospholipid conjugates. Each porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain at one of the sn-1 or the sn-2 positions of one phospholipid. Further, the nanovesicle has a defined regioisomeric ratio of sn-1:sn-2 porphyrin-phospholipid conjugates.

Abstract: A magnetic resonance imaging (MRI) apparatus suitable for radiotherapy. The apparatus includes two sets of coil pairs, each coil pair forming a Maxwell-like coil. The two sets of coil pairs share a common transverse plane, have opposing polarities, and define a common plane of symmetry and an imaging area. The two sets generate a substantially homogenous electromagnetic field in a first transverse direction in the imaging area and peripheral electromagnetic fields in a direction opposite to the first transverse direction in a peripheral area. The apparatus also includes at least one focusing magnet positioned in the peripheral areas to generate a focusing electromagnetic field in a focusing area, in a direction substantially the same as the first transverse direction. At least a portion of the peripheral electromagnetic fields is maintained in a defocusing area between the focusing area and the imaging area.

Abstract: Provided are signal modifying compositions for medical imaging comprising a carrier and two or more signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect to the signal modifying agents, which enables prolonged contrast imaging without significant depletion of the signal modifying agents from the carrier. The carriers of the present invention are lipid based or polymer based, the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal.

Abstract: The disclosure provides methods and materials for increasing the expression of a protein of interest such as an antibody by a cell ABC50 expression or activity is increased which increases expression of the protein or antibody of interest. The disclosure also provides methods and materials for increasing the sensitivity of a cell to an endoplasmic reticulum stress agent such as Econazole by decreasing the level of ABC50.

Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.

Abstract: Provided herein are products, uses and method classifying a subject afflicted with breast cancer according to a ClinicoMolecular Triad Classification (CMTC)-1, CMTC-2 or CMTC-3 class. The method involves: (i) determining a subject expression profile, said subject expression profile comprising the mRNA expression levels of a plurality of genes that classify breast cancer into three groups by hierarchal clustering TN and Her2+ breast cancers into one class (CMTC genes), in a breast cancer cell sample taken from said subject; (ii) calculating a measure of similarity between said subject expression profile, and one or more of: a) a CMTC-1 reference profile, b) a CMTC-2 reference profile, and c) a CMTC-3 reference profile; and (iii) classifying said subject.

Abstract: The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject.

Abstract: A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Abstract: There is provided herein methods, compounds and methods for identifying compounds, for sensitizing a subject with cancer to a cancer therapy by inhibiting or down-regulating UROD.

Abstract: Augmented reality apparatus (10) for use during intervention procedures on a trackable intervention site (32) are disclosed herein. The apparatus (10) comprises a data processor (28), a trackable projector (14) and a medium (30) including machine-readable instructions executable by the processor (28). The projector (14) is configured to project an image overlaying the intervention site (32) based on instructions from the data processor (28). The machine readable instructions are configured to cause the processor (28) to determine a spatial relationship between the projector (14) and the intervention site (32) based on a tracked position and orientation of the projector (14) and on a tracked position and orientation of the intervention site (32). The machine readable instructions are also configured to cause the processor to generate data representative of the image projected by the projector based on the determined spatial relationship between the projector and the intervention site.

Abstract: The present disclosure relates to certain new and known triazolium and/or imidazolium salts and to their therapeutic use, for example in methods of treating or preventing an infection by a Plasmodium or Babesia parasite in a subject in need thereof. The triazolium and imidazolium salts are compounds of the Formula (I) or (II): wherein R1-R4, R1?-R3?, R8-R11, X, X?, X?, Y, Y? and Y? are as defined in the disclosure.

Abstract: The present teachings provide a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract: The present disclosure describes methods and compositions for diagnosing or predicting likelihood of a OSCC recurrence in a subject having undergone OSCC resection comprising: a) determining an expression level of one or more biomarkers selected from Table 4, 5 and/or 7, optionally MMP1, COL4A1, THBS2 and/or P4HA2 in a test sample from the subject, the one or more biomarkers comprising at least one of THBS2 and P4HA2, and b) comparing the expression level of the one or more biomarkers with a control, wherein a difference or a similarity in the expression level of the one or more biomarkers between the test sample and the control is used to diagnose or predict the likelihood of OSCC recurrence in the subject In particular, the present disclosure describes methods and compositions using a four-gene biomarker signature that can predict recurrence of oral squamous cell carcinoma in subjects that have histologically normal surgical resection margins.

Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.

Abstract: Methods and systems for automated treatment planning for radiation therapy are disclosed. Such methods and systems may be useful for treatment planning for intensity-modulate radiotherapy (IMRT). Also provided are user interfaces for automated radiation therapy treatment planning.

Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.

Abstract: A phantom for simulation of perfusion, for use in dynamic flow imaging. The phantom includes a first compartment having a first inlet and a first outlet, and a second compartment having a second outlet. The first and the second compartments have fluid communication with each other, to simulate perfusion between the first and the second compartments. The first and the second outlets are separately controllable to adjust outflow of fluid from each compartment and to adjust fluid pressure in each compartment, thereby controlling rates of communication of fluids between the first and the second compartments.